Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Soo Ryang Kim

Showing results (81-90 of 92) with videos related to

Pageof 10
Sort By:
Digestive Diseases (Basel, Switzerland)|November 28, 2013
Outcome of double-filtration plasmapheresis plus interferon treatment in nonresponders to pegylated interferon plus ribavirin combination therapyKayo Sugimoto, Soo Ryang Kim, Ahmed El-Shamy, et al.
Journal of Gastroenterology|August 31, 2002
Development of multicentric hepatocellular carcinoma after completion of interferon therapySoo Ryang Kim, Toshiyuki Matsuoka, Yoko Maekawa, et al.
Journal of Gastroenterology and Hepatology|April 28, 2005
Multiple hypervascular liver nodules in a heavy drinker of alcoholSoo Ryang Kim, Yoko Maekawa, Toshiaki Ninomiya, et al.
Digestive Diseases (Basel, Switzerland)|October 18, 2017
Serum IFN-λ3 Levels Correlate with Serum Hepatitis C Virus RNA Levels in Symptomatic Patients with Acute Hepatitis CSusumu Imoto, Soo Ryang Kim, Keisuke Amano, et al.
Digestion|December 14, 2011
Correlation between insulin resistance and outcome of pegylated interferon and ribavirin therapy, hepatic steatosis, hepatic fibrosis in chronic hepatitis C-1b and high viral loadSoo Ryang Kim, Jun Saito, Susumu Imoto, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|April 4, 2002
CEA producing primary hepatic carcinoidSoo Ryang Kim, Susumu Imoto, Yoko Maekawa, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|October 1, 2010
Efficacy and safety of double filtration plasmapheresis in combination with interferon therapy for chronic hepatitis CShuichi Kaneko, Michio Sata, Tatsuya Ide, et al.
International Journal of Molecular Medicine|March 21, 2014
Mutational diversity of NS5A and NS3 during triple therapy (telaprevir, pegylated-interferon-α 2b and ribavirin) for genotype 1b chronic hepatitis C: The Kobe Hepatitis Therapeutic GroupFugui Bai, Yoshihiko Yano, Soo-Ryang Kim, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 4, 2013
Hepatitis C virus relapse was suppressed by long-term self-injection of low-dose interferon in patients with chronic hepatitis C after pegylated interferon plus ribavirin treatmentTomoyuki Takashima, Hirayuki Enomoto, Toshiaki Ninomiya, et al.
Internal Medicine (Tokyo, Japan)|December 17, 2013
Clinical characteristics of patients who developed hepatocellular carcinoma after hepatitis C virus eradication with interferon therapy: current status in JapanAkira Sato, Michio Sata, Kenji Ikeda, et al.
Pageof 10

Showing results (81-90 of 92) with videos related to

Sort By:
Pageof 10
Digestive Diseases (Basel, Switzerland)|November 28, 2013
Outcome of double-filtration plasmapheresis plus interferon treatment in nonresponders to pegylated interferon plus ribavirin combination therapyKayo Sugimoto, Soo Ryang Kim, Ahmed El-Shamy, et al.
Journal of Gastroenterology|August 31, 2002
Development of multicentric hepatocellular carcinoma after completion of interferon therapySoo Ryang Kim, Toshiyuki Matsuoka, Yoko Maekawa, et al.
Journal of Gastroenterology and Hepatology|April 28, 2005
Multiple hypervascular liver nodules in a heavy drinker of alcoholSoo Ryang Kim, Yoko Maekawa, Toshiaki Ninomiya, et al.
Digestive Diseases (Basel, Switzerland)|October 18, 2017
Serum IFN-λ3 Levels Correlate with Serum Hepatitis C Virus RNA Levels in Symptomatic Patients with Acute Hepatitis CSusumu Imoto, Soo Ryang Kim, Keisuke Amano, et al.
Digestion|December 14, 2011
Correlation between insulin resistance and outcome of pegylated interferon and ribavirin therapy, hepatic steatosis, hepatic fibrosis in chronic hepatitis C-1b and high viral loadSoo Ryang Kim, Jun Saito, Susumu Imoto, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|April 4, 2002
CEA producing primary hepatic carcinoidSoo Ryang Kim, Susumu Imoto, Yoko Maekawa, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|October 1, 2010
Efficacy and safety of double filtration plasmapheresis in combination with interferon therapy for chronic hepatitis CShuichi Kaneko, Michio Sata, Tatsuya Ide, et al.
International Journal of Molecular Medicine|March 21, 2014
Mutational diversity of NS5A and NS3 during triple therapy (telaprevir, pegylated-interferon-α 2b and ribavirin) for genotype 1b chronic hepatitis C: The Kobe Hepatitis Therapeutic GroupFugui Bai, Yoshihiko Yano, Soo-Ryang Kim, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 4, 2013
Hepatitis C virus relapse was suppressed by long-term self-injection of low-dose interferon in patients with chronic hepatitis C after pegylated interferon plus ribavirin treatmentTomoyuki Takashima, Hirayuki Enomoto, Toshiaki Ninomiya, et al.
Internal Medicine (Tokyo, Japan)|December 17, 2013
Clinical characteristics of patients who developed hepatocellular carcinoma after hepatitis C virus eradication with interferon therapy: current status in JapanAkira Sato, Michio Sata, Kenji Ikeda, et al.
Pageof 10